Julie C Nienstedt1, Alexander Gröbe2, Patrick Lebok3, Franziska Büscheck3, Till Clauditz3, Ronald Simon4, Asmus Heumann3,5, Guido Sauter3, Christoph Moebius6, Adrian Münscher7, Rainald Knecht7, Marco Blessmann6, Max Heiland2, Christina Pflug1. 1. Center for Clinical Neurosciences, Department of Voice, Speech and Hearing Disorders, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Center for Clinical Neurosciences, Oral & Maxillofacial surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 4. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. r.simon@uke.de. 5. Center for Surgical Sciences, Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Center for Surgical Sciences, Department of Plastic, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Center for Clinical Neurosciences, Department of Otolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
OBJECTIVES: CD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Tissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry. RESULTS: Membranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival. CLINICAL RELEVANCE: In summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.
OBJECTIVES:CD151 is a plasma membrane protein belonging to the tetraspanin family. CD151 represents a putative therapeutic target and has been suggested as a prognostic marker in several cancer types. The present study aims to investigate the prognostic relevance of immunohistochemical CD151 expression in head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Tissue microarray (TMA) sections containing samples from 667 cancers of oral cavity, oro- and hypopharynx and larynx, for which follow-up data were available, were analyzed for CD151 expression by immunohistochemistry. RESULTS: Membranous CD151 immunostaining was recorded in 269 (60.3 %) of 446 analyzable cases. Staining was considered weak in 129 (28.9 %), moderate in 98 (22.0 %), and strong in 42 (9.4 %) of cancers. CD151 expression was unrelated to histological grade, tumor stage, nodal status, or surgical margin. There was a tendency towards a somewhat lower prevalence of CD151 expression in tumors of the oral cavity (52.9 % positive) as compared to cancers of the oro-hypopharynx (62.1 %) and larynx (63.3 %; p = 0.0100). CD151 expression had no impact on patient survival. CLINICAL RELEVANCE: In summary, immunohistochemical analysis of CD151 lacks prognostic utility in HNSCC. The high prevalence of CD151 expression in HNSCC emphasizes its putative relevance as a therapeutic target for further development of anti-CD151 drugs.
Entities:
Keywords:
CD151; Head and neck cancer; Immunohistochemistry; Prognosis
Authors: Yoshito Takeda; Alexander R Kazarov; Catherine E Butterfield; Benjamin D Hopkins; Laura E Benjamin; Arja Kaipainen; Martin E Hemler Journal: Blood Date: 2006-10-05 Impact factor: 22.113
Authors: Kolja Freier; Stefan Joos; Christa Flechtenmacher; Frauke Devens; Axel Benner; Franz X Bosch; Peter Lichter; Christof Hofele Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Vanja Karamatic Crew; Nicholas Burton; Alexander Kagan; Carole A Green; Cyril Levene; Frances Flinter; R Leo Brady; Geoff Daniels; David J Anstee Journal: Blood Date: 2004-07-20 Impact factor: 22.113
Authors: Alexander Gröbe; Henning Hanken; Ahmed Al-Dam; Georg Cachovan; Ralf Smeets; Antje Krohn; Till Clauditz; Tobias Grob; Ronald Simon; Guido Sauter; Lan Kluwe; Max Heiland; Marco Blessmann Journal: Clin Oral Investig Date: 2013-02-13 Impact factor: 3.573
Authors: Q Li; X H Yang; F Xu; C Sharma; H-X Wang; K Knoblich; I Rabinovitz; S R Granter; M E Hemler Journal: Oncogene Date: 2012-07-23 Impact factor: 9.867
Authors: M Yáñez-Mó; A Alfranca; C Cabañas; M Marazuela; R Tejedor; M A Ursa; L K Ashman; M O de Landázuri; F Sánchez-Madrid Journal: J Cell Biol Date: 1998-05-04 Impact factor: 10.539
Authors: H Hashida; A Takabayashi; T Tokuhara; N Hattori; T Taki; H Hasegawa; S Satoh; N Kobayashi; Y Yamaoka; M Miyake Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640